Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Algs - You Need To See This

Inside Apex Legends Season 29: Respawn discusses Axle, Trident removal, and movement changes

In an exclusive interview with Dot Esports, Respawn Entertainment discusses how Axle was designed, why Apex Legends is becoming more movement-focused, and the reasoning behind removing Tridents and adding Deathbox Respawns in Season 29.

From homeless to world champion: Monsoon claims glory at ALGS Year 5 Champs

From homeless to world champion: Monsoon claims glory at ALGS Year 5 Champs

Cinderella story for Monsoon.

ALGS Year 6 calendar revealed with $7 million in prize pool

ALGS Year 6 calendar revealed with $7 million in prize pool

Year 6 features $7 million prize pool across three international LANs

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

ALGS Year 5 Championship results: Unsigned team Oblivion win

The Apex Legends Global Series Year 6 winner has been crowned.

ImperialHal makes history with 2,000 career ALGS kills

ImperialHal has hit the 2000-kill milestone with a buffer of over 250 Kills to Zer0.

How to get ALGS Year 5 Champs Twitch drops

Watch the best Apex teams and get some goodies.

Between dedicated drop zones and a new aura cosmetic, I might just grind Apex ranked next season

Now you can pretend it's the ALGS and sweat even harder.

inkl

Read news from The Economist, FT, and more,
with one subscription

Apex Legends pro refuses to eliminate disconnected opponent during $2 million tournament

Apex Legends pro refuses to eliminate disconnected opponent during $2 million tournament

TSM's ImperialHal isn't one for unsportsmanlike conduct, even when money is on the line.

USA Today Sports Media Group

Aligos Therapeutics's Return On Capital Employed Insights

Aligos Therapeutics's Return On Capital Employed Insights

According to Benzinga Pro data, during Q1, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $2.57 million. Earnings were up 5.57%, but Aligos Therapeutics still reported an overall loss of $35.62 million.

Where Aligos Therapeutics Stands With Analysts

Where Aligos Therapeutics Stands With Analysts

Within the last quarter, Aligos Therapeutics (NASDAQ:ALGS) has observed the following analyst ratings:

Aligos Pulls Plug On Early-Stage Chronic Hepatitis B Treatment Candidate

Aligos Pulls Plug On Early-Stage Chronic Hepatitis B Treatment Candidate

Aligos Therapeutics Inc (NASDAQ: ALGS) has

Looking Into Aligos Therapeutics's Return On Capital Employed

Looking Into Aligos Therapeutics's Return On Capital Employed

Aligos Therapeutics (NASDAQ:ALGS) brought in sales totaling $367.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 13.86%, resulting in a loss of $37.71 million.

Recap: Aligos Therapeutics Q4 Earnings

Recap: Aligos Therapeutics Q4 Earnings

Aligos Therapeutics (NASDAQ:ALGS) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Aligos Therapeutics Earnings Preview

Aligos Therapeutics Earnings Preview

Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts estimate that Aligos Therapeutics will report an earnings per share (EPS) of $-0.83.

Get all your
news in one place.

100's of premium titles.
One news app.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Respawn Entertainment

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play